sEV-based Vaccines

About Ciloa Bio

Ciloa Bio is a private, preclinical-stage biotech founded in 2016 and based in Montpellier, France. The company has developed a proprietary platform, EVENGI, for engineering small extracellular vesicles (sEVs) to carry therapeutic payloads, with a lead program (APN-sEVs) targeting obesity and type 2 diabetes. Ciloa has secured significant non-dilutive funding, including a recent €6.5 million grant from France 2030, and engages in strategic partnerships to advance its pipeline in metabolic diseases, vaccines, and oncology.

Therapeutic Areas